Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XOMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXOMA stockholders approve 925,000 shares for equity compensation, adopt litigation forum limits
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved adding 425,000 shares to the 2010 equity plan (extended to 2036) and a new 500,000-share employee stock purchase plan, increasing potential dilution by ~10% of current outstanding shares.
Item 5.02, 5.03 verify on EDGAR → -
medium
Board amended bylaws to require shareholders to sue in Nevada state court for corporate claims and federal court for securities claims, limiting shareholders' choice of legal venue.
Item 5.03 verify on EDGAR → -
medium
Bylaws now clarify Nevada's controlling interest statutes, which require shareholder approval before large acquirers can vote their shares—relevant to pending Ligand merger.
Item 5.03 verify on EDGAR → -
low
All seven directors re-elected with 99%+ approval; Deloitte ratified as auditor; executive compensation approved with 99% support in non-binding say-on-pay vote.
Item 5.07 verify on EDGAR →
Summary
XOMA held its annual meeting on May 21, 2026, where shareholders approved significant expansions to equity compensation programs. The company will add 925,000 shares across two plans—a 425,000-share increase to the existing 2010 Long Term Incentive Plan (now extended through 2036) and a new 500,000-share Employee Stock Purchase Plan.
For context, this represents meaningful potential dilution for existing holders, though such plans are standard tools for retaining talent in biotech. The Board also amended bylaws to add exclusive forum provisions, requiring state corporate law disputes be heard in Nevada state court and federal securities claims in federal court.
This limits where shareholders can sue and may increase litigation costs for plaintiffs. The bylaws also now explicitly reference Nevada's controlling interest statutes, which require shareholder approval before large acquirers can vote newly acquired shares—a provision that becomes relevant given XOMA's pending merger with Ligand Pharmaceuticals. Retail holders should watch for the first grants under these expanded equity plans in upcoming proxy filings, as the size and recipients will indicate management's compensation philosophy. The forum selection clauses are now standard in many companies but do tilt the playing field toward management in disputes.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company’s stockholders approved (i) an amendment and restatement of the Company’s 2010 Long Term Incentive and Stock Award Plan (as so amended and restated, the “Plan”), which increases the shares of common stock available for issuance under the Plan by 425,000 shares and extends the term of the Plan to March 16, 2036
Stockholders approved expanding the 2010 equity compensation plan by 425,000 shares and extending its term to 2036. This increases the pool of shares available for employee and executive equity awards, which can dilute existing shareholders but is intended to retain and incentivize talent.
Added in current filing · verify on EDGAR →
the Company’s stockholders approved ... (ii) the Company’s 2026 Employee Stock Purchase Plan (the “ESPP”), which provides for 500,000 shares of common stock to be available for issuance under the ESPP
Stockholders approved a new employee stock purchase plan with 500,000 shares available. ESPPs typically allow employees to purchase company stock at a discount, which can increase employee ownership but also creates additional dilution for existing shareholders.
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
XOMA amended bylaws to add Nevada controlling interest statute language and exclusive forum provisions for litigation.
Added in current filing · verify on EDGAR →
effective May 21, 2026, the Board of Directors adopted and approved amendments to the Company’s bylaws (the “Bylaws”) to: (1) include language related to the Nevada controlling interest statutes, including Nevada Revised Statutes 78.378 through 78.3793, inclusive, to help clarify the applicability of these statutes
The Board amended the company's bylaws to add language clarifying how Nevada's controlling interest statutes apply. These statutes govern when a shareholder acquiring a controlling interest must obtain approval from other shareholders before exercising voting rights. This change provides clarity on governance procedures in connection with the previously disclosed merger agreement with Ligand Pharmaceuticals.
Added in current filing · verify on EDGAR →
(2) introduce an exclusive forum provision, which provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for certain state corporate law or stockholder derivative claims, and that the federal district courts shall be the sole and exclusive forum for any claim arising under the federal securities laws, in each case to the fullest extent permitted by law and unless the Company consents in writing to the selection of an alternative forum.
The company added a forum selection clause requiring shareholders to bring state corporate law claims in Nevada state court and federal securities claims in federal court, unless the company agrees otherwise in writing. This limits where shareholders can sue the company and may make litigation more expensive or difficult for shareholders, as they cannot choose their preferred venue.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
XOMA Royalty held its Annual Meeting on May 21, 2026, where shareholders elected all seven director nominees and approved all proposals.
Added in current filing · verify on EDGAR →
Proposal 3. Approval of an Amendment and Restatement of the 2010 Long Term Incentive and Stock Award Plan
7,738,322 | 668,915 | 10,195 | 695,090
Shareholders approved an amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan with 7,738,322 votes for versus 668,915 against. Additionally, shareholders approved a new 2026 Employee Stock Purchase Plan with 8,351,699 votes for. These plans will govern future equity-based compensation for employees and executives.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on was approved.
All seven director nominees were elected to the board: Owen Hughes, Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Barbara Kosacz, Joseph M. Limber, and Matthew D. Perry. Vote counts ranged from approximately 8.3 million to 8.3 million votes for each nominee, with minimal withheld votes.
Added in current filing · verify on EDGAR →
Proposal 2. Ratification of Selection of Deloitte & Touche LLP as Independent Auditor
9,041,336 | 12,019 | 59,167 | 0
Shareholders ratified the selection of Deloitte & Touche LLP as the company's independent auditor with 9,041,336 votes for, 12,019 against, and 59,167 abstentions. This represents overwhelming approval with no broker non-votes.
Added in current filing · verify on EDGAR →
Proposal 5. Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers
8,330,043 | 76,630 | 10,759 | 695,090
Shareholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers with 8,330,043 votes for and only 76,630 against. This strong approval indicates shareholder support for the company's executive compensation practices.
Event · Item 9.01 — Financial Statements and Exhibits
XOMA filed bylaw amendments and updated equity compensation plans effective May 21, 2026.
Added in current filing · verify on EDGAR →
XOMA Royalty Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan.
The company amended and restated its 2010 Long Term Incentive and Stock Award Plan. The 8-K does not provide details on what changes were made to the plan, such as share reserve increases or eligibility modifications.
Added in current filing · verify on EDGAR →
XOMA Royalty Corporation 2026 Employee Stock Purchase Plan.
The company adopted a new 2026 Employee Stock Purchase Plan. The 8-K does not disclose plan terms such as discount rates, contribution limits, or share reserves allocated to the plan.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Amendments to Bylaws of the Company, effective May 21, 2026.
The company amended its bylaws effective May 21, 2026. The 8-K does not disclose the specific changes made to the bylaws, only that amendments were adopted and are attached as an exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify